Abstract
Bacillus licheniformis α-amylase (BLA) is routinely used as a model thermostable amylase in biochemical studies. Its starch hydrolysis activity has recently been studied in Tris buffer. Here, we address the question that whether the application of Tris buffer may influence the results of BLA activity analyses. Based on the inhibition studies and docking simulations, we suggest that Tris molecule is a competitive inhibitor of starch-hydrolyzing activity of BLA, and it has a high tendency to bind the enzyme active site. Hence, it is critically important to consider such effect when interpreting the results of activity studies of this enzyme in Tris buffer.
Keywords: BLA, Tris inhibition, buffer inhibition, activity, docking, French bean, glucuronic acid, lectin, mitogenic activity, HepG2, breast cancer, glycoproteins, N-acetylgalactosamine-binding, polysaccharides, inflammation,, thrombosis, metastasis, Phaseolus vulgaris, AKTA Purifier, PBS, SDS-PAGE, HPLC, MCF7, CNE1, CNE2, MTT, Affi-gel blue gel, FPLC, hemagglutinating, N-acetylglucosamine, Aprotinin, Ovalbumin, Temperature, CNE, PHAs, ATP, Con A, chromatography, gel filtration, anti-HIV reverse transcriptase
Protein & Peptide Letters
Title: Binding of Tris to Bacillus licheniformis α-Amylase Can Affect Its Starch Hydrolysis Activity
Volume: 15 Issue: 2
Author(s): Zahra Ghalanbor, Nasser Ghaemi, Sayed-Amir Marashi, Massoud Amanlou, Mehran Habibi-Rezaei, Khosro Khajeh, Bijan Ranjbar, Yau Sang Chan, Jack Ho Wong and Tzi Bun Ng
Affiliation:
Keywords: BLA, Tris inhibition, buffer inhibition, activity, docking, French bean, glucuronic acid, lectin, mitogenic activity, HepG2, breast cancer, glycoproteins, N-acetylgalactosamine-binding, polysaccharides, inflammation,, thrombosis, metastasis, Phaseolus vulgaris, AKTA Purifier, PBS, SDS-PAGE, HPLC, MCF7, CNE1, CNE2, MTT, Affi-gel blue gel, FPLC, hemagglutinating, N-acetylglucosamine, Aprotinin, Ovalbumin, Temperature, CNE, PHAs, ATP, Con A, chromatography, gel filtration, anti-HIV reverse transcriptase
Abstract: Bacillus licheniformis α-amylase (BLA) is routinely used as a model thermostable amylase in biochemical studies. Its starch hydrolysis activity has recently been studied in Tris buffer. Here, we address the question that whether the application of Tris buffer may influence the results of BLA activity analyses. Based on the inhibition studies and docking simulations, we suggest that Tris molecule is a competitive inhibitor of starch-hydrolyzing activity of BLA, and it has a high tendency to bind the enzyme active site. Hence, it is critically important to consider such effect when interpreting the results of activity studies of this enzyme in Tris buffer.
Export Options
About this article
Cite this article as:
Ghalanbor Zahra, Ghaemi Nasser, Marashi Sayed-Amir, Amanlou Massoud, Habibi-Rezaei Mehran, Khajeh Khosro, Ranjbar Bijan, Sang Chan Yau, Ho Wong Jack and Bun Ng Tzi, Binding of Tris to Bacillus licheniformis α-Amylase Can Affect Its Starch Hydrolysis Activity, Protein & Peptide Letters 2008; 15 (2) . https://dx.doi.org/10.2174/092986608783489616
DOI https://dx.doi.org/10.2174/092986608783489616 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Molecular Guidance System Based Upon Target Genes, Nuclear Receptors and Ligands Applied to Drug Discovery and Prediction of Toxicity
Mini-Reviews in Medicinal Chemistry Recent Advances in Optical Cancer Imaging of EGF Receptors
Current Medicinal Chemistry Role of Integrated 18-F FDG PET/CT in Recurrent Ovarian Cancer
Current Medical Imaging Chitosan and Its Use in Design of Insulin Delivery System
Recent Patents on Drug Delivery & Formulation Recent Patents on Imaging Nanoprobes for Brain Tumor Diagnosis and Therapy
Recent Patents on Biotechnology Pterostilbene as a Potential Novel Telomerase Inhibitor: Molecular Docking Studies and Its in vitro Evaluation
Current Pharmaceutical Biotechnology LINE-1 Methylation is Associated with an Increased Risk of Ischemic Stroke in Men
Current Neurovascular Research Immunotherapy: A Potential Approach to Targeting Cancer Stem Cells
Current Cancer Drug Targets The Association of Palmitoylethanolamide with Luteolin Decreases Neuroinflammation and Stimulates Autophagy in Parkinson's Disease Model
CNS & Neurological Disorders - Drug Targets Radiopharmaceutical: Revolutionary Agents for Diagnosis
Current Radiopharmaceuticals Continuous Hypoxia and Glucose Metabolism: The Effects on Gene Expression in Mcf7 Breast Cancer Cell Line
Endocrine, Metabolic & Immune Disorders - Drug Targets Polyphenols: Potential Future Arsenals in the Treatment of Diabetes
Current Pharmaceutical Design Localization Patterns of Sumoylation Enzymes E1, E2 and E3 in Ocular Cell Lines Predict Their Functional Importance
Current Molecular Medicine Mitochondrial Dysfunction in Gliomas: Pharmacotherapeutic Potential of Natural Compounds
Current Neuropharmacology An Insight to Colon Targeted Drug Delivery System
Drug Delivery Letters Targeting Synthetic Lethality in DNA Damage Repair Pathways as an Anti-Cancer Strategy
Current Drug Targets Patent Selections
Current Biomarkers (Discontinued) Human Microdialysis
Current Pharmaceutical Biotechnology Recent Advances In Developing Novel Anti-Cancer Drugs Targeting Tumor Hypoxic and Acidic Microenvironments
Recent Patents on Anti-Cancer Drug Discovery Role of Angiogenesis Inhibitors in Colorectal Cancer: Sensitive and Insensitive Tumors
Current Cancer Drug Targets